Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in High-Grade Squamous Intraepithelial Lesions of the Cervix
NCT00072540Phase 2Withdrawn
- Sponsor
- SWOG Cancer Research Network
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial in squamous intraepithelial lesion of the cervix (SIL) and Cervical Cancer (CC) comparing Celecoxib with Placebo (2 arms). Primary endpoint: Complete Response Rate at 3 months. Status: withdrawn.
02
Drugs
celecoxib
03
Conditions
squamous intraepithelial lesion of the cervix (SIL)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00072540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072540.